Home/ Stocks/ DMAC

DiaMedica Therapeutics Inc. Common Stock

DMAC XNAS

$6.89 -0.39 (-5.35%) ▼ 15-min delayed

Open

$7.15

High

$7.28

Low

$6.79

Volume

210.0K

Market Cap

$379.64M

About DiaMedica Therapeutics Inc. Common Stock

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 28 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	N/A	$-8,620,000	$-0.17
Q2 2025	N/A	$-7,699,000	$-0.18
Q1 2025	N/A	$-7,707,000	$-0.18
FY 2024	$0	$-24,444,000	$-0.60

Related Market News

No specific coverage for DMAC yet. Check out our latest market news or earnings calendar.

Get DMAC Alerts

Stay ahead with breaking news, price alerts, and expert analysis on DiaMedica Therapeutics Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.